New Hampshire nears approval of medical marijuana law
By Jason McLure LITTLETON, New Hampshire (Reuters) - New Hampshire is set to become the final state in New England to allow medical marijuana after negotiators from the Republican-controlled Senate and Democratic-controlled House agreed Tuesday on...

Ohio residents held disabled woman in slavery, government charges
By Kim Palmer CLEVELAND (Reuters) - Three Ohio residents are accused of holding a cognitively disabled woman and her daughter against their will and forcing the woman to perform physical labor for them, threatening her with snakes if she didn'...

Industry-backed studies more prominent at meetings
By Genevra Pittman NEW YORK (Reuters Health) - Studies that are funded by pharmaceutical companies or involve industry-backed scientists tend to be more prominent at cancer meetings than independent studies, a new report suggests. "Figuring o...

Exclusive: Japan's Astellas looks to sell dermatology assets - sources
By Jessica Toonkel NEW YORK (Reuters) - Japanese drugmaker Astellas Pharma Inc is looking to sell its dermatology portfolio, which could be worth between $500 million and $1 billion, according to three people familiar with the situation. Astellas ...

FDA probes deaths of two patients on Lilly schizophrenia drug
By Ransdell Pierson (Reuters) - The Food and Drug Administration is investigating the cases of two individuals who died after injections with Eli Lilly and Co's long-acting treatment for schizophrenia, Zyprexa Relprevv. Both patients died thre...

Enroll America sets private outreach for Obamacare enrollment
By David Morgan WASHINGTON (Reuters) - Enroll America, a nonprofit group at the center of the political fight over President Barack Obama's healthcare reform law, launched a multi-state grassroots campaign on Tuesday to help sign up millions o...

AstraZeneca turnaround is 3-4 year journey, says CEO
By Ben Hirschler LONDON (Reuters) - Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday. Speaking as...

Maine Democrats scramble after governor blocks Medicaid expansion
By Dave Sherwood BOWDOINHAM, Maine (Reuters) - Democratic legislators in Maine scrambled on Tuesday to muster the votes needed to override Republican Governor Paul LePage's late-night veto of a bill to expand Medicaid coverage to an additional...

U.S. patent case climaxes with win for Canadian vibrator maker
WASHINGTON (Reuters) - Couples in the United States looking to spice up their sex lives will have to do without certain adult toys after a U.S. trade panel ruled on Monday that some companies are violating a patent held by a Canadian company for a...

EU fines Lundbeck, 8 others 146 mln euros for blocking cheaper drugs
BRUSSELS (Reuters) - EU antitrust regulators fined nine drugmakers a total of 146 million euros ($195.5 million) on Wednesday for blocking the supply of cheaper medicines on the market, with a penalty of 94 million euros imposed on Denmark's L...